A Phase 1, Blinded, Single Ascending Dose Study to Evaluate Safety, Pharmacokinetics, and Activity of TRL1068 in Subjects With Prosthetic Joint Infection of the Knee or Hip, Undergoing Primary Two Stage Exchange Arthroplasty
Latest Information Update: 15 Apr 2024
At a glance
- Drugs TRL 1068 (Primary)
- Indications Bacterial infections; Bone and joint infections
- Focus Adverse reactions
- Sponsors Trellis Bioscience
- 08 Apr 2024 Status changed from active, no longer recruiting to completed.
- 02 Jan 2024 Planned End Date changed from 1 Feb 2024 to 1 Mar 2024.
- 02 Jan 2024 Planned primary completion date changed from 1 Nov 2023 to 1 Jan 2024.